ABT logo Abbott Laboratories +
Abbott Laboratories
+

Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:30 AM | Tuesday | May 19, 2026 Seeking Alpha

The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential

NEW News Thumbnail
3:17 PM | Monday | May 18, 2026 Zacks Investment Research

Boston Scientific Bets on Growth Through Strategic M&A Deals

News Thumbnail
10:16 AM | Monday | May 18, 2026 Zacks Investment Research

ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

News Thumbnail
10:00 AM | Monday | May 18, 2026 Zacks Investment Research

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

News Thumbnail
10:16 AM | Monday | May 18, 2026 Zacks Investment Research

ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

News Thumbnail
10:00 AM | Monday | May 18, 2026 Zacks Investment Research

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

News Thumbnail
11:16 AM | Friday | May 15, 2026 Zacks Investment Research

How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up

News Thumbnail
10:30 AM | Tuesday | May 12, 2026 Zacks Investment Research

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

News Thumbnail
10:02 AM | Monday | May 11, 2026 Seeking Alpha

Abbott: Three Supercycles, Mispriced At A 10-Year Low

News Thumbnail
8:00 AM | Saturday | May 9, 2026 Seeking Alpha

Abbott Laboratories Is On Sale, Don't Overlook It

News Thumbnail
9:40 AM | Friday | May 8, 2026 Zacks Investment Research

Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

News Thumbnail
8:46 AM | Wednesday | May 6, 2026 Fool - Investing News

Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows

News Thumbnail
10:01 AM | Tuesday | May 5, 2026 Zacks Investment Research

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

News Thumbnail
11:32 AM | Monday | May 4, 2026 Seeking Alpha

Polen Focus Growth Portfolio Q1 2026 Portfolio Update

News Thumbnail

The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential

Seeking Alpha

7:30 AM | Tuesday | May 19, 2026

news photo
Loading...

Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target. ABT, trading at a forward P/E of 15.31x, is undervalued with robust liquidity, ongoing buybacks, and insider buying, despite segment weakness and lowered guidance.

Read full article redirect
7:30 AM | Tuesday | May 19, 2026

The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential

Seeking Alpha

Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target. ABT, trading at a forward P/E of 15.31x, is undervalued with robust liquidity, ongoing buybacks, and insider buying, despite segment weakness and lowered guidance.

Read full article arrow
NEW News Thumbnail
3:17 PM | Monday | May 18, 2026

Boston Scientific Bets on Growth Through Strategic M&A Deals

Zacks Investment Research

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

Read full article arrow
News Thumbnail
10:16 AM | Monday | May 18, 2026

ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

Zacks Investment Research

Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.

Read full article arrow
News Thumbnail
10:00 AM | Monday | May 18, 2026

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read full article arrow
News Thumbnail
10:16 AM | Monday | May 18, 2026

ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

Zacks Investment Research

Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.

Read full article arrow
News Thumbnail
10:00 AM | Monday | May 18, 2026

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read full article arrow
News Thumbnail
11:16 AM | Friday | May 15, 2026

How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up

Zacks Investment Research

ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.

Read full article arrow
News Thumbnail
10:30 AM | Tuesday | May 12, 2026

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Zacks Investment Research

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read full article arrow
News Thumbnail
10:02 AM | Monday | May 11, 2026

Abbott: Three Supercycles, Mispriced At A 10-Year Low

Seeking Alpha

Abbott Laboratories trades at a decade low of 17.7x forward earnings despite 13.2% Q1 2026 Medical Devices growth and a 54-year dividend streak. Three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—could drive $1.27–$1.
73 incremental EPS by 2028–2029. Consensus underestimates ABT's commercial leverage, with distribution synergies and CMS reimbursement expansion offering asymmetric upside not priced into current models.

Read full article arrow
News Thumbnail
8:00 AM | Saturday | May 9, 2026

Abbott Laboratories Is On Sale, Don't Overlook It

Seeking Alpha

Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak.

Read full article arrow
News Thumbnail
9:40 AM | Friday | May 8, 2026

Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

Zacks Investment Research

ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.

Read full article arrow
News Thumbnail
8:46 AM | Wednesday | May 6, 2026

Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows

Fool - Investing News

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

Read full article arrow
News Thumbnail
10:01 AM | Tuesday | May 5, 2026

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read full article arrow
News Thumbnail
11:32 AM | Monday | May 4, 2026

Polen Focus Growth Portfolio Q1 2026 Portfolio Update

Seeking Alpha

In Q1 2026, Polen Focus Growth Portfolio returned -17.27% (net of fees) compared to -9.78% for the Index. Starbucks was the top performing absolute and relative contributor in Q1 amid positive signs that CEO Brian Nicol's multi-year turnaround strategy is beginning to bear fruit. In Q1 2026, we initiated new positions in Lam Research, Meta and Rollins, while we sold our holdings in Abbott Laboratories, Adobe, and Boston Scientific, Paycom and Intuit.

Read full article arrow
News Thumbnail